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Background and objective: Adherence to treatment in patients with psoriasis is often poor. 
An investigation of patient preferences and satisfaction with treatment may be important, based 
on the expected correlation with therapy compliance. This paper aims to examine and describe 
the current literature on patient preferences, satisfaction and adherence to treatment for psoriasis 
in the European Union (EU).
Methods: Electronic searches were conducted using PubMed, ISI Web of Knowledge, Scopus, 
Spanish databases and Google Scholar. European studies published in English or Spanish 
between January 1, 2009 and December 31, 2014 regarding patient-reported outcomes in 
psoriatic patients were included. Studies conducted in non-EU countries, letters to the editor, 
editorials, experts’ opinions, case studies, congress proceedings, publications that did not dif-
ferentiate between patients with psoriasis and psoriatic arthritis or studies related to specific 
treatment were excluded.
Results: A total of 1,769 titles were identified, of which 1,636 were excluded as they were 
duplicates or did not provide any relevant information. After a full-text reading and application 
of the inclusion/exclusion criteria, 46 publications were included. This paper will describe pub-
lications on adherence (n=4), preferences (n=5) and satisfaction with treatment (n=7). Results 
related to health-related quality of life articles (n=30) have been published elsewhere. Adher-
ence rates are generally low in psoriasis patients regardless of the type of treatment, severity 
of disease or methods used to measure adherence. Biologic therapy is associated with greater 
clinical improvement. There is a direct association between physician recommendations, patient 
preferences and several domains of treatment satisfaction.
Conclusion: The results of this review support the conclusion that adherence rates in patients 
with psoriasis are suboptimal and highlight the need to improve patient compliance and sat-
isfaction with treatment. Patients’ preferences should be taken into account in the treatment 
decision-making process in order to improve patients’ clinical outcomes by ensuring satisfac-
tion and adherence.
Keywords: psoriasis, patient preference, adherence, satisfaction, systematic review, patient-
reported outcomes, European Union
Introduction
Psoriasis is a common chronic inflammatory disease of the skin and joints that is 
typically characterized by erythematous papules and plaques.1–3 Estimates of the 
worldwide prevalence of psoriasis range from 1% to 3%4–6 and it affects ~2% of the 
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population in Europe.7,8 The disease can present at any age, 
but the mean age of onset for the first presentation of psoriasis 
ranges from 15 to 20 years, with a second peak occurring 
at 55–60 years.9 Although psoriasis is not a life-threatening 
disease, it has a negative effect on patients’ health-related 
quality of life (HRQoL), similar to that of other major medi-
cal conditions.9–12
The severity of disease is related to the extension of the 
cutaneous manifestations and is defined by the Psoriasis 
Area and Severity Index (PASI) or as a percentage of the 
total body surface area (BSA).13 The majority of psoriasis 
patients suffer from mild disease (PASI #10), which can 
often be managed with topical agents, while phototherapy 
or systemic therapies are usually used for patients with 
moderate-to-severe psoriasis (PASI .10). In the last decade, 
significant advances in the management and treatment of 
psoriasis have been made with the introduction of biologic 
agents,14,15 which have shown greater clinical benefit than 
traditional systemic therapies.16–22
With more than 90% of psoriasis patients having a chronic 
condition, adherence to treatment is crucial for successful 
disease management and reduction in clinical severity.23 
However, it is estimated that nearly 40% of patients with 
psoriasis do not use medication as prescribed.4,24,25 In addi-
tion to non-adherence, psoriasis is consistently associated 
with treatment dissatisfaction.3,26–28 As satisfaction is closely 
associated with patient preferences and compliance with 
treatment,29 taking patients’ opinions about available treat-
ment options into consideration may be crucial to improving 
satisfaction and adherence, thereby increasing the effective-
ness of the treatment and HRQoL.
The introduction of biologic therapies over the past 
10 years has further increased the therapeutic options for 
moderate-to-severe psoriasis. Although all of these biologic 
agents are highly effective and show a favorable risk–benefit 
profile, differences in efficacy, rapidity of action and sustain-
ability do exist. This makes the decision-making process 
regarding the most suitable therapeutic strategy more com-
plex for both patients and physicians, underlining the need to 
elucidate patients’ treatment preferences. This review aims to 
examine and describe the current literature on patient prefer-
ences, satisfaction and adherence to treatment for psoriasis 
in the European Union (EU).
Methods
We performed a systematic review of the literature on 
adherence to treatment, satisfaction with therapy, patient 
preferences for treatment and HRQoL in psoriatic patients in 
the EU. In order to obtain an accurate insight into how novel 
treatment options (available in European countries since 
2005) have influenced patient-reported outcomes (PROs), 
studies from January 1, 2009 to December 31, 2014 were 
included. International (Medline/pubMed, cochrane Ligrary, 
ISI Web of knowledge [ISI WOK], SCOPUS) and Spanish 
electronic databases (Medicina en Español [MEDES], Índice 
Bibliográfico Español en Ciencias de la Salud [IBECS]) and 
Google Scholar were used to search the literature. The English 
and Spanish search terms used are summarized in Table S1.
Original articles, reviews and systematic reviews in 
English or Spanish that evaluated treatment adherence and 
satisfaction, patient preferences for treatment and HRQoL 
in psoriatic patients from a European perspective were 
included in the review. Publications about all of the treat-
ments available for psoriasis (topical, systemic and biologic 
agents) were included. On the other hand, studies conducted 
in non-EU countries, original letters to the editor, editorials, 
experts’ opinions, case studies, congress proceedings, studies 
with mixed populations including patients with psoriasis 
(with or without psoriatic arthritis) and patients with psoriatic 
arthritis alone or studies related to specific treatments were 
excluded. The selection of publications was performed by 
two independent researchers and discrepancies were resolved 
by consensus.
The methodological quality of the studies was assessed by 
assigning a level of evidence and recommendation based on 
criteria developed by the Centre for Evidence-Based Medi-
cine (CEBM).30
Results
A total of 1,769 titles were identified, of which 587 (33.2%) 
were duplicates and therefore excluded. The other 1,182 
(66.8%) were excluded because they did not provide any 
relevant information. After full-text reading and applica-
tion of the inclusion/exclusion criteria, 46 of the remaining 
133 publications were included in the review (Figure 1). 
Twenty-seven (58.7%) articles were related to HRQoL, seven 
(15.2%) evaluated treatment satisfaction, five (10.9%) exam-
ined treatment preferences, four (8.7%) explored treatment 
adherence and three (6.5%) described cumulative life course 
impairment (CLCI). Results related to HRQoL (n=27) and 
CLCI articles (n=3) have been published elsewhere.31
The present article examines and describes the 16 
studies, published in the EU between January 1, 2009 and 
December 31, 2014, that were selected and which related 
to psoriasis patients’ preferences for treatment, adherence 
and satisfaction.
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characteristics of selected studies
These 16 studies included the following designs: 4 conjoint 
analyses, 2 reviews, 1 systematic review, 4 prospective 
studies, 3 cross-sectional studies and 1 retrospective study. 
Nearly half were conducted in Germany (n=7), two in the UK, 
two in Spain, two in the Netherlands, one in Italy and two 
were multicenter studies across different European countries. 
The level of evidence in the majority of the studies (n=12) 
was grade 2c and their CEBM recommendation was grade B, 
which indicates moderate evidence.
Treatment adherence in patients with 
psoriasis
Of the 16 studies, 4 (25%) examined adherence to medical 
therapies. Three of them were reviews, which evaluated 
rates and determinants of adherence, while the fourth article 
selected was a Delphi consensus study conducted in Spain.
The systematic review undertaken by Thorneloe et al32 
consistently reported low rates of treatment adherence, 
regardless of the type of treatment, disease severity or type 
of adherence measurement used (Table 1). Even though 
there were inconsistent findings with regard to the predictive 
factors of adherence, studies investigating the role of psy-
chological factors revealed that increased psychological 
distress and low patient satisfaction with care or therapy 
were associated with lower levels of adherence. In line with 
these results, Bewley and Page24 confirmed that rates of 
adherence to topical medications were low, with 39%–73% 
of psoriasis patients not using medications as prescribed 
and revealed that effectiveness and the characteristics of 
the treatment (cosmetic acceptability) were the main con-
tributors for increasing adherence to psoriasis medication. 
Moreover, they identified that prescribing therapy in line 
with patient preferences or improving patient education may 
Figure 1 PrisMA diagram of systematic review process.
Abbreviations: PrisMA, preferred reporting items for systematic reviews and meta-analyses; eU, european Union; PrOs, patient reported outcomes; P, psoriasis; PsA, 
psoriatic arthritis; hrQol, health related quality of life; clci, cumulative life course impairment.
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result in increased adherence. Similarly, Zschocke et al33 
established that the reasons for non-adherence to treatment 
amongst psoriasis patients revolve mainly around treatment 
vehicle, patient–physician relationship or patient motivation. 
These authors propose that given that the barriers to 
medication adherence are complex and varied, solutions to 
improve adherence should be multifaceted and allow tailoring 
according to each patient’s individual needs.
Finally, the Delphi study conducted by Puig et al34 with 
a panel of experts from the Psoriasis Group of the Span-
ish Academy of Dermatology and Venereology reached 
a consensus that in order to improve adherence to topical 
treatment, it was necessary 1) to improve communication 
between patients and health care staff, 2) to provide written 
instructions and 3) to simplify treatment with easy-to-use and 
pleasant products that were preferably applied only once a 
day. In addition, the panelists agreed that treatment satisfac-
tion increased adherence and tended to improve the HRQoL 
of psoriasis patients, highlighting the relationship between 
treatment satisfaction and treatment adherence.
Taken together, these studies draw attention to the low 
rates of adherence to psoriasis treatments and highlight the 
importance of involving patients in treatment decision-
making, in order to improve their adherence to treatment.
Treatment satisfaction in patients with 
psoriasis
The following section summarizes seven articles related 
to treatment satisfaction of patients with psoriasis and to 
variations depending on type of treatment, demography 
and clinical factors. Five articles used study-specific ques-
tionnaires, while the other two studies assessed patient’s 
satisfaction using the Treatment Satisfaction Questionnaire 
for Medication (TSQM) (Table 2).
Schaarschmidt et al35 revealed the high impact of the 
type of treatment on satisfaction scores. Participants receiv-
ing biologicals (TSQM: 323.3) and traditional systemic 
treatments (TSQM: 288.0) were more satisfied than those 
receiving phototherapy (TSQM: 260.6) or topical agents 
(TSQM: 266.8; P,0.001). These authors also observed that 
high disease-related HRQoL impairment, as measured by the 
Dermatology Life Quality Index (DLQI), and psoriatic arthri-
tis were associated with decreased treatment satisfaction. 
In line with these results, van Cranenburgh et al36 indicated 
that, overall, patients with psoriasis were moderately satis-
fied with their current treatment, with patients receiving 
biologic treatments being the most satisfied, compared to 
other groups (total satisfaction score [range from 5= not 
satisfied to 25= very satisfied]: topical [16.5], phototherapy 
[18.3], systemic [19.5], biologics [0.9]). These authors 
identified age (t[1182] =2.9; P=0.004) and disease severity 
(t[1882] =-18.6; P,0.001) as predictive factors of satisfac-
tion. Similarly, Ragnarson Tennvall et al37 described the 
highest treatment satisfaction, that is, 8.2 (scale of 0 not at all 
satisfied to 10 very satisfied) in patients who had been treated 
with biological drugs for 12 months, followed by patients 
who received systemic treatment for less than 12 months (6.5) 
and patients receiving topical treatment (5.7). Van den Reek 
et al38 confirmed the high satisfaction rates achieved with 
biologic treatment, with statistically significant (P,0.05) 
improvements in the “efficacy”, “convenience” and “global 
satisfaction” domains of TSQM after 3 and 6 months initia-
tion of biologic therapy.
Two studies assessed the relationship between psoriasis 
severity (PASI) and satisfaction. Schäfer et al39 showed that, 
while most patients who achieved PASI 75 (92.3%) indicated 
that their expectations with the treatment were met, this 
applied to only half (53.1%) of patients with PASI 50 and 
Table 1 Adherence rates
Instrument used to determine 
adherence
Adherence definition Adherence rates 
(% of adherent patients)
Patient self-reported measures Adhering to the therapy regimen or advice provided by doctors 27%–61%
Adhering to the application 33%–97%
never or rarely missed a dose of their biological treatment 66.6%
Adhering to the duration of therapy 71% (topical), 80% 
(phototherapy), 83% (systemic)
Using a continuous scale 75%–92%
Pharmacy prescription refill records
Medication possession ratio (MPr)
Proportion of days’ supply obtained during the study period 
divided by the number of days in the study period
14%–66%
Medication weights and counting ratio of doses taken to doses prescribed 60.6%–117.8%
Median of expected dose of topical therapy 35%
Medication event monitoring 
systems (MeMs)
electronically records the opening and closing of medication 
bottle cap
54.6%–67% (topical), 55%–75% 
(systemic and phototherapy)
Note: Data from Thorneloe et al.32
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Table 2 characteristics of treatment satisfaction studies reviewed
Study Objective Design Demographic and clinical 
characteristics of sample
Sample 
treatment
Satisfaction questionnaire 
used
schaarschmidt 
et al35 (germany)
To compare satisfaction 
of patients with 
moderate-to-severe 
psoriasis with all systemic 
psoriasis treatments 
currently approved for 
treatment of psoriasis in 
germany, using TsQM
cross-
sectional
n=200 patients
57.5% male; mean age 
50.8 years (sD: 14.1); mean 
PAsi 3.4 (sD: 4.1); mean 
disease duration: 19.9 years 
(sD: 13.1); 22.5% had 
psoriatic arthritis
18% topical
10% phototherapy
37.5% systemic
43.5% biological
Treatment satisfaction 
questionnaire for medication 
(TsQM) (5-point likert-type 
scale: 1= very dissatisfied; 
5= very satisfied; 4 subscales 
(efficacy, adverse events, 
convenience, overall satisfaction, 
each range: 0–100; total score 
with a maximum of 400 points)
van den reek et al38 
(the netherlands)
To investigate satisfaction 
with medication, as 
measured by the TsQM, 
for biological therapies 
in daily practice psoriasis 
care in the first 6 months 
of treatment
Prospective n=106 patients
58.5% male; mean age 48.2 
(sD: 12.3) years
54% of them were biologics-
naïve; 46% without biological 
treatment in the past
46% adalimumab
32% etanercept
22% ustekinumab
TsQM version ii: 11 items: 
7-point likert-type scale: 
1= extremely dissatisfied; 
7= extremely satisfied; range: 
0–100)
christophers et al40 
(France, germany, 
italy, spain and UK)
To compare clinical 
improvement and 
treatment satisfaction 
with biologic versus 
other therapies
cross-
sectional
n=379 dermatologists and 
2,151 patients with current 
therapy for at least 12 weeks
21% topical
31% phototherapy
32% conventional 
systemic
16% biologic
Ad hoc question (not applicable, 
completely dissatisfied, 
moderately dissatisfied, slightly 
satisfied, highly satisfied, 
completely satisfied)
ragnarson Tennvall 
et al37 (sweden, 
Denmark, Finland)
To examine hrQol and 
treatment satisfaction
retrospective n=404 patients
64% male; mean age 51 years 
(range: 19–77); mean time 
since diagnosis: 20 years 
(range 1–71)
46% topical
36% systemic
18% biological
Ad hoc question (0= not at all 
satisfied; 10= very satisfied)
Van cranenburgh 
et al36 (the 
netherlands)
To determine patient 
satisfaction with their 
current treatment and its 
predictors
To establish the 
importance of specific 
domains of satisfaction
cross-
sectional
n=1,200 patients
53.7% male; mean age 
55.9 years (sD: 12.3); mean 
disease severity (1–5): 
2.5 (sD: 1.1); mean time 
since diagnosis: 28.8 years 
(sD: 15.4): 55.6% patients 
with visible psoriasis; 56.5% 
treatment-naïve patients
46.4% topical
5.9% 
phototherapy
31.3% 
conventional 
systemic
16.3% biologic
Study-specific questionnaire 
(5 items: global satisfaction, 
effectiveness, safety, 
convenience, information; 
5-point likert-type scale: 1= not 
satisfied at all; 5= very satisfied; 
range: 5–25)
ribera et al41 
(spain)
To design and assess the 
validity, reliability, and 
sensibility to change of 
the ssWTPQ for use in 
patients with moderate-
to-severe psoriasis
Prospective n=423 patients
61.9% male; mean age 
45.9 years (sD: 13.9, mean 
PAsi 21.4 (sD: 9.2)
57% topical
20.3% systemic + 
topic
ssWTPQ: 12 items scored 
on 5-point likert scale with 
scores from 0 (very satisfied) to 
5 (very unsatisfied) with a total 
score of 0 to 48
schäfer et al39 
(germany)
To analyze correlation 
between PrOs and PAsi
Prospective n=93 patients
62.4% male; mean age 
49.3 years (sD: 14.1); mean 
PAsi 13.7 (sD: 9.5)
The mean period of 
treatment and observation 
was 42.5 days (sD: 17)
ns Study-specific questionnaire 
(8 items; 1= completely; 4= not 
at all)
Abbreviations: PAsi, Psoriasis Area and severity index; PrOs, patient-reported outcomes; TsQM, Treatment satisfaction Questionnaire for Medication; ssWTPQ, spanish 
Satisfaction with Treatment of Psoriasis Questionnaire; NS, not specified; HRQoL, health-related quality of life; SD, standard deviation.
to 36.4% of patients with lower clinical treatment success 
(PASI ,50). In relation to satisfaction with the condition 
of their skin after therapy, 84.6% of patients who achieved 
PASI 75 were completely or predominantly satisfied; this 
proportion was reduced to 43.7% and 36.4% in the PASI 
50 and PASI ,50 groups, respectively. Christophers et al40 
observed that the percent of PASI reduction in patients with 
severe psoriasis who received biologic therapy was signifi-
cantly greater than in patients who received topical therapy, 
phototherapy or traditional systemic therapy (79% vs 55%, 
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47%, 69%, P,0.001). Thus, a reduction in PASI contributed 
to an increase in treatment satisfaction. More patients receiv-
ing biologic therapy were satisfied (highly or completely) 
with their current treatment than patients receiving any 
other therapy (59% patients receiving biologic therapy vs 
50% patients receiving traditional systemic therapy vs 34% 
patients receiving phototherapy vs 45% patients receiving 
topical agents only; P,0.001).
In line with these results, in a study published by Ribera 
et al,41 with the aim of developing a satisfaction question-
naire (Spanish Satisfaction with Treatment of Psoriasis 
Questionnaire) and assess its validity, reliability and sensi-
tivity to change, patients with severe psoriasis scored higher 
[(0= highest satisfaction; 48= highest dissatisfaction), 27; 
SD: 2.6] than patients with moderate psoriasis (22.6; 
SD: 9.5). These authors described a weak correlation between 
reduction in PASI score during a 12-month study period and 
improvement in satisfaction.
In summary, satisfaction studies indicated that patients 
receiving biologic therapy were more satisfied and their sat-
isfaction was correlated to improvements in clinical features 
(mainly measured by PASI score).
Patient preferences for therapies in 
psoriasis
Five publications examined patient preferences for treatment; 
four of them described the results of a conjoint analysis 
based on a discrete choice experiment that aimed to ana-
lyze the preferences of individuals with moderate or severe 
psoriasis for outcome and process attributes42–45 (Table 3). 
In a study published by Schaarschmidt et al,42 the attribute 
regarded as most important was treatment location (where 
the treatment takes place) (relative importance score [RIS]: 
26.76), followed by probability of benefit (RIS: 23.77) and 
method of delivery (RIS: 23.49). The RISs for all process 
attributes were higher than for adverse effect (AE)-related 
attributes, indicating that participants were willing to 
trade an increased risk of AEs for increased probability 
and magnitude of therapeutic benefit. Age, disease severity 
(PASI score) and household income were the only factors 
that affected preferences. Older participants ($65 years) 
found the probability of benefit less important than younger 
participants (P=0.005); patients with intermediate incomes 
(€1,000–€2,000 per month) granted less importance to treat-
ment delivery method compared with patients with lower 
income; patients with higher PASI score considered the prob-
ability of benefit as less important (P=0.02) but the frequency 
of treatment more important compared with participants 
with a lower PASI score (P=0.04). Schaarschmidt et al43 
described the impact of treatment experience (satisfaction 
with current treatment, number of prior visits, disease dura-
tion, number of preceding therapies and currently prescribed 
treatment modalities) on treatment preferences. With regard 
to disease and treatment duration, participants with longer 
disease duration attached greater importance to the duration 
of benefit (β=0.206, P=0.018), whereas participants on oral 
therapy were more concerned about magnitude of benefit by 
trend (β=0.218, P=0.058). Participants receiving injectable 
therapy not only set higher value to probability of benefit 
(RIS =32.80 vs 21.89, P=0.025) but also to treatment location 
(RIS =44.74 vs 23.03, P=0.011), delivery method and treat-
ment frequency (RIS =31.24 vs 16.89, P=0.005) and duration 
(RIS =32.54 vs 16.57, P=0.003) compared to others.43 These 
results suggest that treatment preferences change over the 
course of time and with treatment experience. Participants 
on injectable therapy attached great importance to the 
effectiveness and convenience of treatment and were highly 
satisfied with it. As reported by Umar et al,44 prolonged 
treatments in the inpatient setting (Mean Preference Score 
[MPS]: -13.48) and those with a lower probability of benefit 
(MPS: -12.28) were the least preferred while treatments with 
a high probability of benefit (MPS: 10.51) were most pre-
ferred. Patients were more concerned about improvement of 
their skin condition than about the reversibility or the sever-
ity of treatment side effects. Using data from the conjoint 
analysis, Umar et al45 published a prospective cohort study 
which assessed the extent to which matching physicians’ 
treatment recommendations to patients’ treatment prefer-
ences was associated with improvement in treatment. The 
results of the study suggested that a closer match between 
physicians’ recommendations and patients’ preferences 
was associated with greater improvement in treatment sat-
isfaction over time in each of the four subscales: effective-
ness (β=0.53, P,0.001), side effects (β=0.25, P=0.009), 
convenience (β=0.78, P,0.001) and global satisfaction 
(β=0.49, P,0.001).
Finally, Torbica et al46 conducted a discrete choice 
experiment on 244 Italian psoriatic patients. Overall, patients 
preferred the subcutaneous or intravenous route of admin-
istration (vs oral administration) and treatments that took 
less time to show improvement, ensured a longer time free 
of symptoms, involved a lesser reduction in life expectancy 
and had lower costs. In general, older patients placed sig-
nificantly greater importance on reduced life expectancy, 
whereas time free of symptoms was less important to them 
than to patients under 60 years of age. Patients with high 
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DLQI scores placed higher value on time free of symptoms 
than those with lower DLQI scores.
Data from these studies offer a focus on patients’ prefer-
ences for psoriasis treatment and suggest that when making 
decisions about treatment, the heterogeneity of patient’s 
expectations and preferences should be considered in order 
to identify individualized treatments that would aid in opti-
mizing patient satisfaction and well-being, as well as overall 
treatment effectiveness.
Discussion
Despite the heterogeneity of the articles selected in terms 
of patients, treatment and methodology features, the infor-
mation obtained from the studies included in this review 
provides an assessment of the challenge of non-adherence 
in psoriasis, together with an identification of patients’ 
preferences and levels of satisfaction regarding the medi-
cations currently approved for the treatment of psoriasis 
in the EU.
Table 3 characteristics of preferences related studies reviewed
Study Objective Design Demographic and 
clinical characteristics 
of sample
Sample 
treatment
Attributes/levels
schaarschmidt 
et al42 
(germany)
To analyze the 
preferences of 
individuals with 
moderate or severe 
psoriasis for outcome 
attributes (treatment 
location, frequency, 
duration, delivery 
method and individual 
cost) of psoriasis 
treatment conjoint analysis 
based on a discrete 
choice experiment
n=163 patients
58.9% male; mean age 
49.3 years (sD: 14.1); 
mean PAsi 5.6 (sD: 5.6), 
PAsi 0–5 (61.3%), PAsi 
5.1–10 (23.9%), PAsi 
,10 (14.7%)
37.4% topical
14.1% 
phototherapy
27.6% oral 
systemic therapy
17.2% injected 
systemic therapy
Outcome attribute: Probability of 
benefit (almost 100%; about 80%, 
about 60%, about 40% reduction); 
magnitude of benefit (almost 100%, 
about 75%, about 50%, about 
25% reduction in size); duration 
of benefit ($1 year, 6–8 months, 
3–5 months, 2 weeks after 
completing treatment); Probability 
of Aes (almost 100%, about 50%, 
about 10%, ,1%); reversibility of 
Aes (almost 100%, about 80%, about 
60%, about 40%); Ae severity (minor 
discomfort, moderate discomfort, 
moderate Aes, severe Aes)
Process attribute: location (home, 
home with follow-up, outpatient, 
hospital), frequency (1/3 months, 
1/2 weeks, 2/week, 2/day); delivery 
method (topical, oral, injection, UV), 
duration (5 min, 15–30 min, 1 h, 2 h); 
cost (€0, additional €50/month; 
€100/month; €200/month)
schaarschmidt 
et al43 
(germany)
To assess the impact of 
treatment experience on 
treatment preferences
Umar et al44 
(germany)
To examine the features 
of psoriasis treatment 
that are most and 
least preferred by 
patients and to identify 
correlates of these 
preferences
Umar et al45 
(germany)
To assess the extent 
to which matching 
physician’s treatment 
recommendations to 
patient’s treatment 
preferences is associated 
with improvement in 
treatment satisfaction
Prospective cohort 
study based on 
data from conjoint 
analysis
n=132 patients, 38.6% 
women; mean age 
50.2 years (sD; 14.2); 
mean disease duration: 
18.3 year (sD: 14.2)
– TsQM questionnaire
Torbica et al46 
(italy)
To assess patient 
preferences for psoriasis 
treatment features 
and to investigate 
the heterogeneity of 
preferences among 
patients with different 
sociodemographic 
and disease-related 
characteristics
conjoint analysis 
based on a discrete 
choice experiment
n=243 patients
62.1% male; mean age 
48.8 years (sD: 13.9);
 PAsi grade 0 (0.4%), 
PAsi grade 1 (4.1%), 
PAsi grade 2 (86.9%), 
PAsi grade 3 (8.6%)
84.7% topical
37.5% systemic
38.5% biological
Mode and frequency of therapy 
administration (oral daily; 
intravenous monthly; subcutaneous 
quarterly), time to improvement 
(1, 3, 6 months); time free of 
symptoms (2, 4, 6 months); reduced 
life expectancy (1, 2, 3 months); 
monthly treatment cost not covered 
by the nhs (€0, €100, €500)
Abbreviations: PAsi, Psoriasis Area and severity index; sD, standard deviation; Ae, adverse event; UV, ultraviolet; TsQM, Treatment satisfaction Questionnaire for 
Medication; nhs, national health system.
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According to the results reported, adherence rates in 
patients with psoriasis were generally low and were influ-
enced by multiple factors, such as the characteristics of 
patients and the treatments, treatment effectiveness, patient–
physician relationship or patient motivation. However, 
findings were inconsistent with regard to predictive factors 
of adherence.
In addition to treatment adherence, this review investi-
gated current knowledge regarding patient preferences and 
satisfaction with available treatment options for psoriasis. 
The results highlight that patients receiving biologic treat-
ment were consistently more satisfied compared to those 
receiving traditional systemic therapies, while patients 
receiving topical therapies were the least satisfied. Moreover, 
the positive association between clinical treatment success 
and satisfaction suggested that the use of effective drugs that 
provide greater reduction in disease severity (PASI score) 
may contribute to higher rates of satisfaction.
Several studies conducted outside the EU support 
these results. Overall satisfaction scores, as measured by 
the TSQM, obtained in a cross-sectional study of 1,182 
moderate-to-severe psoriasis patients conducted by Callis 
Duffin et al47 in the US, were highest for patients receiving 
biologic monotherapies, biologic combinations or photo-
therapy (83.3), while scores were lowest for those receiving 
topical therapies only (66.7). Significant correlations were 
found between overall survival and both PASI (ρ=-0.36, 
P,0.001) and DLQI (ρ=-0.47, P,0.001). Similarly, Finch 
et al48 reported that levels of satisfaction with phototherapy 
and systemic treatments were high; conversely, there were 
higher levels of dissatisfaction with topical treatments.
Regarding patients’ preferences, psoriasis patients attach 
greater importance to process attributes (treatment location, 
method of delivery, frequency, duration and cost) than to 
outcome attributes (probability, magnitude or duration of 
benefit and AE probability, reversibility or severity) when 
selecting treatment. Although the probability of benefit was 
also highly considered, psoriasis patients appear to be willing 
to accept treatment-related AEs if the process characteristics 
of psoriasis treatment provide a better fit with their personal 
and professional life. Treatment preferences may change 
over time and with treatment experience. Recently, in a study 
conducted by Kromer et al,49 the most important attributes in 
relation to biologic agents for patients with moderate-to severe 
psoriasis were safety (probability of severe AE) and efficacy 
(probability of 90% improvement). With regard to efficacy, 
although a 75% improvement in PASI score (PASI 75) is 
generally considered the gold standard of treatment efficacy 
in the clinical setting in patients with psoriasis,50 when the 
advances obtained with biologic therapy are considered, 
PASI 90 may represent the best meaningful clinical response, 
particularly in patients with very severe psoriasis.51
Additionally, these authors have revealed that preferences 
vary with sociodemographic characteristics and working 
status. Of note, men were more concerned about the prob-
ability of symptom improvement than women, and women 
attached greater value to treatment frequency than men. 
Older participants judged the probability of improvement 
less important than younger patients but they worried more 
about severe side effects. Finally, patients with a full-time 
job gave more value to time until response, treatment location 
and treatment frequency than non-working patients.49
In line with these data, a review that aimed to examine 
the published evidence regarding patient preferences and 
satisfaction in rheumatoid arthritis,52 process attributes, such 
as vehicle, and treatment location attributes were also very 
important for patients with rheumatoid arthritis. In addition, 
when given a choice among various therapeutic options, 
these patients chose a biologic or combination therapy that 
included a biologic agent.
The overall results suggested that incorporating patient 
preferences into treatment decision-making may contribute 
to improve treatment satisfaction, adherence and thus, clini-
cal outcome.
Possible limitations of this review included the small 
number of papers retrieved. This may be due to the exclusion 
of studies published before the introduction of biologic 
treatments. In addition, there may be relevant papers in 
languages other than English or Spanish or that are indexed 
in databases other than those searched, which we did not 
identify. Nevertheless, as all the studies included European 
populations, this review reflects the disease characteristics of 
homogeneous populations in industrialized countries.
Finally, it is important to point out that, although there 
were differences between study designs, populations, 
outcome parameters and the treatments compared among 
the publications included, the information with regard to 
adherence and PROs in psoriasis that was obtained from 
our comprehensive search was very robust and valuable 
in terms of facilitating shared decision-making during the 
clinical encounter.
Conclusion
The results of this review support the conclusion that 
adherence rates in patients with psoriasis are suboptimal, 
highlight the need to improve treatment compliance and 
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add satisfaction with treatment to enhance the HRQoL for 
patients with psoriasis. To this end, a better understanding 
of the factors that motivate and discourage patient participa-
tion in treatment is necessary. Patient preferences should be 
taken into account in the treatment decision-making process 
in order to improve patients’ clinical outcomes by ensuring 
satisfaction and adherence.
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The study was sponsored by Novartis Farmacéutica S.A. The 
authors report no other conflicts of interest in this work.
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Table S1 search terms and research strategies used in international and spanish databases
International databases
(psoriasis [Mesh term] nOT psoriatic arthritis) AnD (quality of life [Mesh term] Or qol Or health related quality of life Or hrqol Or adherence 
Or persistence Or compliance Or satisfaction Or preferences Or utility Or cumulative life course impairment Or clci)
Spanish databases
(psoriasis) AnD (calidad de vida Or calidad de vida relacionada con la salud Or adherencia Or persistencia Or cumplimiento Or satisfacción Or 
preferencias Or utilidad Or discapacidad acumulada) 
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